Artis BioSolutions, a prominent biotechnology firm, has acquired Syngoi Technologies for an undisclosed amount. Syngoi Technologies is known for its innovative approach to producing linear, covalently locked, minimal DNA constructs. This acquisition marks a strategic expansion for Artis BioSolutions into advanced DNA synthesis capabilities, integrating Syngoi's patented cell-free production methods into its operations.
Syngoi Technologies specializes in synthesizing oDNA containing natural and/or non-natural nucleotides as adaptors. Their proprietary cell-free production methods enable the manufacturing of these DNA constructs under GMP conditions. This process is distinguished by its scalability, cost-effectiveness, high-fidelity, and significantly faster production times compared to traditional pDNA methods, while also offering customisation options for specific research and therapeutic applications.
The acquisition is strategically significant for Artis BioSolutions, aiming to enhance its portfolio and accelerate development in areas requiring precise and efficient DNA constructs. Syngoi's technology offers a robust platform for generating high-quality genetic material, which can be critical for various applications, including gene therapy, vaccine development, and advanced biological research. The integration of Syngoi's capabilities is expected to create synergies by streamlining the development and manufacturing of novel biological solutions within Artis BioSolutions.
This move is anticipated to strengthen Artis BioSolutions' position in the competitive life sciences market by offering superior, rapidly produced DNA constructs. The combined entity is poised to leverage Syngoi's innovative production platform to drive further advancements in biotechnology, potentially expanding market reach and accelerating the delivery of next-generation genetic tools and therapies.